Nortriptyline Hydrochloride

Indications and usage: Nortriptyline hydrochloride is indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states.

CLINICAL PHARMACOLOGY The mechanism of mood elevation by tricyclic antidepressants is at present unknown. Nortriptyline hydrochloride is not a monoamine oxidase inhibitor. It inhibits the activity of such diverse agents as histamine, 5-hydroxytryptamine, and acetylcholine. It increases the pressor effect of norepinephrine but blocks the pressor response of phenethylamine. Studies suggest that nortriptyline hydrochloride interferes with the transport, release, and storage of catecholamines.

Pharmacokinetic profiling of Nortriptyline Hydrochloride demonstrates an elimination half-life of Terminal t½ estimated at 4–11 hrs depending on renal/hepatic reserve (Nortriptyline Hydrochloride) with F ≈ 51%–63% systemic availability after standard oral Nortriptyline Hydrochloride administration systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across nortriptyline hydrochloride regimens, reaching clinical onset within time to peak concentration spans 1 to 4 hrs under nortriptyline hydrochloride maintenance.

Titration schedules for Nortriptyline Hydrochloride (50 mg/1 Capsule → 75 mg/1 Capsule → 25 mg/1 Capsule → 10 mg/1 Capsule → 10 mg/5mL Solution) require excluding prior anaphylaxis, angioedema, or severe hypersensitivity to nortriptyline hydrochloride or nortriptyline hydrochloride excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2025-12-26 nortriptyline hydrochloride spl; real-world patient logs highlight nausea (8.5% of reports), headache (7.1% of reports), insomnia (6.1% of reports) alongside a 87.00% Worth-It consensus.